Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a research report report published on Tuesday.

Pulse Biosciences Stock Performance

PLSE traded down $0.22 during midday trading on Tuesday, reaching $16.89. The company had a trading volume of 17,907 shares, compared to its average volume of 203,017. The business has a 50-day moving average of $17.36 and a two-hundred day moving average of $14.93. Pulse Biosciences has a 1 year low of $5.97 and a 1 year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) earnings per share for the quarter. During the same quarter last year, the firm earned ($0.19) EPS.

Institutional Trading of Pulse Biosciences

Hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers increased its position in Pulse Biosciences by 6.7% in the second quarter. Rhumbline Advisers now owns 25,729 shares of the company’s stock worth $288,000 after purchasing an additional 1,608 shares during the last quarter. BNP Paribas Financial Markets raised its position in Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after purchasing an additional 2,952 shares in the last quarter. Quest Partners LLC purchased a new stake in Pulse Biosciences in the second quarter worth about $91,000. Bank of New York Mellon Corp lifted its position in shares of Pulse Biosciences by 23.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after purchasing an additional 9,639 shares during the period. Finally, Price T Rowe Associates Inc. MD bought a new stake in Pulse Biosciences during the 1st quarter valued at $88,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.